{"name":"Iconic Therapeutics, Inc.","slug":"iconic-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPUTdMV3hNWW15bXJnUG1zb3pYbHM2QzlJRGZ3ZUZZY3ZBZXJZOWJlbHNWTDJFQmVxWnhwV0JiZDNfM254alNvZElvb1BaeFQ1UFhBRzh3dkhlX0V1S0c2WnF6eUNXSm1xcXcxcFJuSW1vd1JPVVJ1Vl9fVEJpV19tV3BPSnZqOWJfeFRjeVQ2TlJ3cFh5WkpSTHZwRQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Yahoo Finance","summary":"Creation of Wampole Group L.P.: A strategic milestone in centralizing its operations across a portfolio of 12 iconic brands - Yahoo Finance","headline":"Creation of Wampole Group L.P.: A strategic milestone in centralizing its operations across a portfolio of 12 iconic bra","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-22","type":"regulatory","source":"Medical Dialogues","summary":"JnJ seeks USFDA approval for Icotrokinra to treat plaque psoriasis in adults, adolescents - Medical Dialogues","headline":"JnJ seeks USFDA approval for Icotrokinra to treat plaque psoriasis in adults, adolescents","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-06-17","type":"deal","source":"Mint","summary":"Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - Mint","headline":"Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPejI4bUhWenlJOG9CR3UtNHJXamI4TXhLbGRaY2stczUzVlBYd3hUWXFYX0E1cG1VTnFrS3ZOVlJTb1FkYjM2ZDM1SFlEdjgxXzVfVzhET1dpUllJaVE3c3MzTzh6b3ZYQzFUYjlDYmdlZFZ5RWR4bm03Nkh3NlQ0NjFuSzBwbjNiSEVlWEV6aDltUmtqU1dQMHFQWlR5U0taTjFZUWFoZnNOSG5wMncyclJ0YWdzSjdyRVIwag?oc=5","date":"2025-03-11","type":"pipeline","source":"Healio","summary":"‘Coming to the clinic soon’: Top AAD takeaways from Joel M. Gelfand, MD, MSCE - Healio","headline":"‘Coming to the clinic soon’: Top AAD takeaways from Joel M. Gelfand, MD, MSCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOYzBYLV9mTUY0VEY1V3JmTEVXZk40SjFDSXc0cFhrekFMcHoxVjFsNmdPcFU0ZWhJa1QtYlNzamdfU19oVm5Oelc5UjVmMHU0WGVHS0hUSlpRTjBVZm96TXNvQ3RwdkU2RUdaZUJBXzlmdml1WVVyMUN0OVNBV1NKb1F1RzNCS3N6NEJ3VTNNak1jMVU3bU1MUkw1M3VjWXlmc0JqQ09xb3BST3AwRUNvY2hpaldFNWhhYnQ4T2hKMTd6X29Yb2VGOWlveThENERoSFFtdzVxR0JlSlBvT0FyZ1BCaFo?oc=5","date":"2025-01-24","type":"trial","source":"ACCESS Newswire","summary":"Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks","headline":"Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPX2M0U183MmxxWTRHMlZPa2pDVFFzM3JYenBRd3VRRG5mXzNCcURoNDJSYjdfblcxTEl1cE1wY1ZvTkR4bkR2RzJBMnNOMHdtRHQ5OWZaWFJJMDl3WDlqQ2NnbDRJTjNRZGEza25fVEpBRWoxTzNuc2VfTXVHdFVFQWh6R0E1cXMteU5FLU5SLUtiR2ZqdmhrSVhxMlFSYVE?oc=5","date":"2024-11-19","type":"pipeline","source":"BioPharma Dive","summary":"J&J pill clears skin in two late-stage psoriasis studies - BioPharma Dive","headline":"J&J pill clears skin in two late-stage psoriasis studies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPME5uWXM0Y1FEVGtwTk5zNnB6OUViQXltUzFJNl9yUkhZc0NadjFjM21zRXpwS0FqSU5xSERFUEdwZGExbzNNS1RiOEFpMVBuMXZGVDVYZmI4NjZxdmxkM1pJak5hOWJLM2RfbWVoLXNJVWpic05hQWt3WnFVUDZsakNkdDFwU2l2ZFJETUVPVzVlLWtORUhfaWNLeFhPX1hzWFYzNkFzYkU1WHhSZjlJSWRn?oc=5","date":"2024-11-13","type":"pipeline","source":"PRWeek","summary":"Johnson & Johnson’s Vanessa Broadhurst helps iconic brand reengage with consumers - PRWeek","headline":"Johnson & Johnson’s Vanessa Broadhurst helps iconic brand reengage with consumers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOX05WUVdHSkF6V3dDNnhTTzJ4UFhyNmdubUtiQ19TMWkwTDc2RW02Qm9SN1RBMExYbHg4MzQ5NC1YXzFoQjJxXy1sdm9iMTVKMWx4aUNYR3MyX0puUHpNbEVHQU55TlliVTBQUDV3SWstMHJLMzhfVkFCbDBrc1JvNWFTekE?oc=5","date":"2024-01-03","type":"pipeline","source":"Pharma Voice","summary":"Why J&J rebranded its iconic logo - Pharma Voice","headline":"Why J&J rebranded its iconic logo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE83OWFoQVJNcjhrcjZfQllVTl9XUzlwQml0ZEFoUlNGcGZhNVlaTjRfLWpBVDZ1cEs2RzJROWNDVEw5NmU1T0ZJYjhrSGp0SjhWbG5DWlpVR1I2VVhodmlv?oc=5","date":"2023-10-26","type":"earnings","source":"Nature","summary":"Prediction of activity in eyes with macular neovascularization due to age-related macular degeneration using deep learning - Nature","headline":"Prediction of activity in eyes with macular neovascularization due to age-related macular degeneration using deep learni","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNMjM5a3E1QkFWT28waHU0V2RHQVAzSkQtWmNsRVFzcFd2WFdxSVJlQWNKWkFldnVYekEtdmZpX3FUQ1N6MXpTVXh3dVpnN0hJRjd1SDlnaGxjcWkxMmU1WndkYjBIWjVRVzhGS0o2Vm1uZ3FtdllTck9mTk1ZMnBodHE3amNXcEgxVks3OWtuODRBRWVCd2tmWE1nYUhER3BPM3p5OWZPbko5anBIbE5QTXRoWGN5QXgy?oc=5","date":"2023-04-04","type":"deal","source":"citybiz","summary":"WellSpring Consumer Healthcare Acquires Iconic OTC Skin Care Brands From Bayer - citybiz","headline":"WellSpring Consumer Healthcare Acquires Iconic OTC Skin Care Brands From Bayer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPMXVZUlRjUEJLaHBqNzdzODNaaUVrU1lVVmlJNFZYcG5wdExWeUY2cFVTLW15dXpYdm85TUo4dFBfWWVWZUJjV296ZHVWOTVjM2doUHJHTmdUbDBQUXc4OEljWWoxX2l0YVFJMS15QU5qcjJUZVBIdjAyQVkzMXBwZXhnR2l6SHFhNXNrTkE0SGZfeEs2ME5xMjRrc0pGUjQyLTFKQlhNN08xQzVkbXhKN3NPV0hWcFctTktTUGs1cWZUS3JyM1FNVW02WWZZM1hpNlNVMWtsWFlhTmp6NWd5Wmd2enhIeG5JV0pNU01VNkk5MVBjb1QyZEtULTVoVm85STYzZGpUcEFnNE9KTWVGcl9jVQ?oc=5","date":"2022-01-06","type":"deal","source":"businesswire.com","summary":"Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor - businesswire.com","headline":"Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tiss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxOUW5XYkhZT00xZmRlRERIQ0xEdUEyTEZhbHFqck9xODgxd2l2ZGluTUx1N3RGMVVabFE4ZWRTZDE1OFhZWkxsbmF3T1RQMEwyR19YRDk1Tk45SlFGME9PNnA2OTlXcS1oSGprMVh3dEZHOERwTmxiV3MzbExnMGdNQnFLajlpNHY0aUJaVlI4QjdDQTMtV1A3eGxCQUF3YkRDcUxhaG9LdklacTQwWTZvdjVkMW1qQUQ0ZTlLaUJ5dGhWdUtwcnA4aFprUjhVdEZjenQ0Ym56VEdEeG5hWjN0eDFqWUlVRFI2VmFheVlReTI5MmQ3a29RMEJrRUZkNWtfYm43MjYtaVp4LUtKWGhwdEhVS2l2MzBWenp3bTJldTRGeE1IV1pGaHFHanZnLW9ncWV2TlI2VFg1RDBHQXVPbXAzZk82TVcxZk1oM1Zn?oc=5","date":"2019-04-15","type":"trial","source":"prnewswire.com","summary":"Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat - prnewswire.com","headline":"Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}